EyeTech: Primary Care Dollars for Specialty Pharma

Pfizer's $295 million deal for EyeTech's product for macular degeneration is one more example of the Big Pharma's evident belief in the increasing value of specialist, as opposed to primary care, markets. For Pfizer, co-promoting the drug with a start-up is less problematic than most such arrangements because of EyeTech's deep connections with thought leaders in the field and Pfizer's own inexperience in it.

Arbitrage may be the biggest game in biotech.

For $7 million up front and $25 million in milestones, plus the ability to buy a big chunk of stock...

More from Archive

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.